![Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years - The Lancet Regional Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years - The Lancet Regional](https://www.thelancet.com/cms/attachment/94906954-5ccb-4653-9abd-d5d757f99af6/gr1_lrg.jpg)
Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years - The Lancet Regional
![Special Mission” : Recruitment of M23 Rebels to Suppress Protests in the Democratic Republic of Congo | HRW Special Mission” : Recruitment of M23 Rebels to Suppress Protests in the Democratic Republic of Congo | HRW](https://www.hrw.org/sites/default/files/styles/opengraph/public/multimedia_images_2017/201711africa_drc_main.jpg?itok=Zl551W0t)
Special Mission” : Recruitment of M23 Rebels to Suppress Protests in the Democratic Republic of Congo | HRW
![Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study - The Lancet Respiratory ... Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study - The Lancet Respiratory ...](https://www.thelancet.com/cms/attachment/c916b04a-9a00-4859-9ff4-d0fb6b2ba3d2/gr1.gif)
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study - The Lancet Respiratory ...
![Optimising experimental research in respiratory diseases: an ERS statement | European Respiratory Society Optimising experimental research in respiratory diseases: an ERS statement | European Respiratory Society](https://erj.ersjournals.com/sites/default/files/highwire/erj/51/5.cover-source.jpg)